DASATINIB

作品数：30被引量：53H指数：5
导出分析报告
相关领域：医药卫生更多>>
相关作者：杨波何俏军黄常康叶建胜邵雪晶更多>>
相关机构：浙江大学山西医科大学中国科学院大学江苏先声药物研究有限公司更多>>
相关期刊：《World Journal of Gastrointestinal Pathophysiology》《Journal of Biomedical Research》《国外药讯》《中国药物化学杂志》更多>>
相关基金：国家自然科学基金北京市自然科学基金中国博士后科学基金山西省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Repurpose dasatinib and quercetin:Targeting senescent cells ameliorates postmenopausal osteoporosis and rejuvenates bone regeneration被引量：3
《Bioactive Materials》2023年第7期13-28,共16页Ying Wang Lingbin Che Xi Chen Zirui He Dianwen Song Yuan Yuan Changsheng Liu 
Frontiers Science Center for Materiobiology and Dynamic Chemistry(No.JKVD1211002);Natural Science Foundation of China for Innovative Research Groups(No.51621002);National Natural Science Foundation of China(Nos.81571828,31971264,32101151);Basic Science Center Project of National Natural Science Foundation of China(T2288102)。
Clinical therapies developed for estrogen-deficiency-driven postmenopausal osteoporosis(PMO)and related diseases,such as bone degeneration,show multiple adverse effects nowadays.Targeting senescent cells(SnCs)and the ...
关键词：Postmenopausal osteoporosis Dasatinib and quercetin Senescent cells Mesenchymal stem cell Bone regeneration 
Clinical Efficacy of Dasatinib in the Treatment of Chronic Myeloid Leukemia (CML) Patients with Different Clinical Stages
《Journal of Clinical and Nursing Research》2022年第5期9-13,共5页Yudi Miao 
Objective:To study the efficacy of dasatinib treatment in different clinical stages of patients with chronic myeloid leukemia(CML).Methods:A total of 80 patients with chronic myeloid leukemia(CML)were selected for exp...
关键词：DASATINIB Different clinical stages Chronic myeloid leukemia Clinical efficacy 
Phosphorylation-mediated interaction between human E26 transcription factor 1 and specific protein 1 is required for tumor cell migration
《Acta Biochimica et Biophysica Sinica》2022年第10期1441-1452,共12页Xianhui Wen Xingsheng Sun Zheyuan Ou Jun Jiang Qingmei Chen Xirong He Zhangsheng Hu Han Qiao Kuan Zhou Xin Li Yiqun Deng Jikai Wen 
supported by the grants from the Joint Fund of the Department of Education of Guangdong Province(No.2018KZDXM015);the National Natural Science Foundation of China(No.31471234);the Special Funds for the Cultivation of Guangdong College Students′Scientific and Technological Innovation(“Climbing Program”,No.pdjh2020b0091).
Transcription factors,human E26 transcription factor 1(Ets1)and specific protein 1(Sp1),are known to induce gene expression in tumorigenicity.High Ets1 expression is often associated with colorectal tumorigenesis.In t...
关键词：protein interactions ETS1 SP1 PP2 DASATINIB colon cancer 
Clinical Effect of Imatinib,Nilotinib,and Dasatinib on Chronic Myeloid Leukemia in Chronic Phase
《Journal of Clinical and Nursing Research》2022年第4期17-21,共5页Yudi Miao 
The study was conducted to explore the effect of imatinib,nilotinib,and dasatinib in the treatment of chronic myeloid leukemia(CML)patients.Around 66 patients with CML in chronic phase were selected,subsequently the p...
关键词：IMATINIB NILOTINIB DASATINIB Chronic myeloid leukemia Chronic phase Clinical effect 
Carrier-free prodrug nanoparticles based on dasatinib and cisplatin for efficient antitumor in vivo被引量：2
《Asian Journal of Pharmaceutical Sciences》2021年第6期762-771,共10页Lu Yang Jiaxi Xu Zheng Xie Faquan Song Xin Wang Rupei Tang 
supported by the National Natural Science Foundation of China(No.51803001 and 51503001);the Natural Science Foundation of Anhui Province(No.2008085ME136 and 2008085QE210);the Research Foundation of Education Department of Anhui Province of China(No.KJ2018ZD003,KJ2018A0006 and KJ2019A0015);the Academic and Technology Introduction Project of Anhui University(AU02303203)grant.
Carrier-free drug self-delivery systems consisting of amphiphilic drug-drug conjugate(ADDC)with well-defined structure and nanoscale features have drawn much attention in tumor drug delivery.Herein,we report a simple ...
关键词：PRODRUG NANOPARTICLE DASATINIB CISPLATIN 
达沙替尼(dasatinib)通过上调上皮钙黏蛋白表达抑制SK-Hep-1人肝癌细胞的增殖、分散和迁移被引量：2
《细胞与分子免疫学杂志》2021年第9期801-807,共7页刘畅 裴晋红 穆秀丽 于保锋 
山西省自然科学基金(201901D111190,2015011113);山西省重点研发计划(国际合作)项目(201703D421023);长治医学院博士科研启动基金(BS202007)。
目的研究多靶点激酶抑制剂达沙替尼(dasatinib)对SK-Hep-1人肝癌细胞增殖、黏附和迁移能力的影响及机制。方法先采用dasatinib处理SK-Hep-1、Bel-7402、SNU-423、SNU-387、Huh-7肝癌细胞,噻唑蓝(MTT)法检测dasatinib对肝癌细胞存活和增...
关键词：达沙替尼(dasatinib) SK-Hep-1细胞 上皮钙黏蛋白(E-cadherin) 黏附 迁移 
Dasatinib inhibits proliferation of liver cancer cells,but activation of Akt/mTOR compromises dasatinib as a cancer drug被引量：5
《Acta Biochimica et Biophysica Sinica》2021年第7期823-836,共14页Chang Liu Xiaoxia Zhu Yuqi Jia Fenqing Chi Keru Qin Jinhong Pei Chan Zhang Xiuli Mu Hongwei Zhang Xiushan Dong Jun Xu Baofeng Yu 
This work was supported by the grants from the National Natural Science Foundation of China(Nos.30901821 and 82072737);Nature Science Project of Shanxi Province,China(Nos.201701D121165 and 201901D111190);Research Project Supported by Shanxi Scholarship Council of China(No.2020-194);Key R&D Projects in Shanxi Province,China(No.201703D421023);Open Fund from Key Laboratory of Cellular Physiology(Shanxi Medical University),Ministry of Education,China(No.KLMEC/SXMU-202011);Shanxi l1331 Project5 Key Subjects Construction,China(No.1331KSC);Scientific Research Starting Foundation for Doctor of Changzhi Medical College(No.BS202007).
Dasatinib is a multi-target protein tyrosine kinase inhibitor.Due to its potent inhibition of Src,Abl,the platelet-derived growth factor receptor(PDGFR)family kinases,and other oncogenic kinases,it has been investigat...
关键词：DASATINIB SNU-449 SK-Hep-1 Akt-mTOR signaling 
Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia a prospective study from a single center
《China Medical Abstracts(Internal Medicine)》2021年第2期119-120,共2页ZHANG Guangji 
Objective To evaluate the efficacy and safety of dasatinib combined with a multi-agent chemotherapy regimen of Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph^(+)ALL)patients.Methods This prospective,...
关键词：REGIMEN PROSPECTIVE LYMPHOBLASTIC 
Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase
《China Medical Abstracts(Internal Medicine)》2020年第2期111-112,共2页YUAN Ting 
Objective To explore the efficacy and prognosis of nilotinib or dasatinib as second-or third-line treatment in patients with chronic myeloid leukemia(CML)in the chronic phase(CP)and accelerated phase(AP).Methods From ...
关键词：PATIENTS MYELOID LEUKEMIA 
Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase
《China Medical Abstracts(Internal Medicine)》2019年第3期181-181,共1页CHEN Yilin 
Objective To investigate the efficiency and safety of domestic tyrosine kinase inhibitor(TKI)dasatinib(Yinishu)as second-line treatment for patients with chronic myeloid leukemia in chronic phase(CML-CP).Methods A ret...
关键词：PATIENTS MYELOID TREATMENT 
全选清除导出
共3页<123>
检索报告 对象比较 聚类工具 使用帮助 返回顶部